Shingles vaccine among patients with psoriasis, rheumatoid arthritis not linked with increased risk of shingles

July 3, 2012

Although some have suggested that patients receiving medication for immune-mediated diseases such as rheumatoid arthritis or psoriasis may be at increased risk of herpes zoster (HZ; shingles) shortly after receipt of the vaccine, an analysis that included nearly 20,000 vaccinated Medicare beneficiaries finds that the live zoster vaccine is not associated with an increased risk of HZ shortly after vaccination in patients currently treated with biologics, and that it is associated with a significantly reduced longer-term risk of HZ in patients with an immune-mediated disease, according to a study in the July 4 issue of JAMA.

"A live attenuated vaccine reduces HZ risk by 70 percent and 51 percent among immunocompetent individuals 50 to 59 years and 60 years and older in 2 randomized blinded trials, respectively," according to background information in the article. "The risk of HZ is elevated by 1.5 to 2 times in with rheumatic and immune-mediated diseases such as and Crohn's disease. This increase has been attributed to both the underlying disease process and treatments for these conditions." Currently, the (FDA) and other organizations consider the live HZ vaccine to be contraindicated in patients receiving some immunosuppressive medications commonly used to treat these conditions, including all immune-modulating and some nonbiologic immunosuppressive medications. The safety concern is that these individuals may develop varicella infection from the vaccine , the authors write.

Jie Zhang, Ph.D., of the University of Alabama at Birmingham, and colleagues, evaluated patients with immune-mediated diseases. The retrospective cohort study included 463,541 60 years and older with rheumatoid arthritis, psoriasis, psoriatic arthritis, (a form of of the spine), or using Medicare claims data from January 2006 through December 2009. The researchers measured the incidence rate of herpes zoster within 42 days after vaccination (a safety concern) and beyond 42 days.

The average age of the patients at the start of follow-up was 74 years, with the median (midpoint) duration of follow-up being 2 years; 72 percent of the patients were women, and 86 percent were white. During the study, 18,683 patients (4.0 percent) received the zoster vaccine.

The researchers found that among 633 patients exposed to biologics, including 551 patients exposed to anti-tumor necrosis factor (TNF) biologics, no cases of varicella or HZ occurred within the 42 days following vaccination. Among all patients, only 1 case of primary varicella was identified within the 42-day risk window, occurring on day 10 after vaccination.

During the period of more than 42 days after vaccination, the researchers observed 138 HZ cases. After controlling for demographics, type of immune-mediated disease, health care utilization, and exposure to biologic and nonbiologic disease-modifying antirheumatic drugs (DMARDs) and oral glucocorticoids, data indicated that vaccination was associated with decreased HZ risk over a median of 2 years of follow-up.

"Despite the recognition that patients with immune-mediated conditions are at increased risk of HZ, this and previous studies have shown that only a small fraction of these patients received the vaccine, likely in part due to safety concerns. Our data call into question the current recommendations that HZ vaccine is contraindicated in patients receiving biologics and suggest a need for a randomized controlled trial to specifically address the safety and effectiveness of HZ vaccination among patients receiving biologics," the authors conclude.

Explore further: Study challenges concerns on effectiveness of administering pneumococcal, shingles vaccines together

More information: JAMA. 2012;308[1]:43-49.

Related Stories

Study challenges concerns on effectiveness of administering pneumococcal, shingles vaccines together

May 12, 2011
Administering both the pneumococcal and the herpes zoster vaccines to patients during the same visit is beneficial and does not appear to compromise the protective effect of the zoster vaccine, according to a Kaiser Permanente ...

Treatment with anti-TNFs can increase the risk of shingles by up to 75 percent

June 7, 2012
Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional ...

Recommended for you

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

December 9, 2017
Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening ...

Location, location, location: Immunization delivery site matters

December 1, 2017
In vaccination, a certain subpopulation of dendritic cells is vital to triggering the body's adaptive immune system, report researchers at The Jackson Laboratory (JAX), Yale University and Astra-Zeneca.

An anti-aging protein could be targeted to rejuvenate immune cells

November 30, 2017
Anti-aging proteins have long been shown to protect against age-related diseases, such as cancer, neurodegeneration, and cardiovascular disease. A study by researchers at the Gladstone Institutes now reveals that one such ...

Scientists find key to miscarriages in blood clotting disorder

November 28, 2017
Monash University researchers have potentially shed light on why women with the rare autoimmune disorder Antiphospholipid syndrome (APS) are prone to successive pregnancy losses.

How do cells release IL-1? After three decades, now we know

November 28, 2017
Researchers at Boston Children's Hospital have identified, for the first time, the molecule that enables immune cells to release interleukin-1 (IL-1), a key part of our innate immune response to infections. Findings were ...

Why do more women have asthma than men? Blame hormones

November 28, 2017
Women are twice as likely as men to have asthma, and this gender difference may be caused by the effects of sex hormones on lung cells. Researchers at Vanderbilt University and Johns Hopkins found that testosterone hindered ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

pozloves
not rated yet Jul 04, 2012
Genital herpes can be transmitted even if a person has no symptoms,suggesting a high risk of transmission from people with unrecognized infections of herpes simplex 2, researchers said on Tuesday. You can check more tips on a herpes support and dating site ==herpesanddating.net== It is a popular online dating for h people.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.